AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25818798 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 50
Study 25818798 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 50
Study 23509040 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS group (treating to a DAS28 of <2.6)
Number of subjects: 308
Study 23509040 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-SJC group (treating to a 0 of 28 swollen joint count)
Number of subjects: 308
Study 23509040 — intervention group
Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 308
Study 23509040 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS group
Number of subjects: 308
Study 23509040 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-SJC group
Number of subjects: 308
Study 21462215 — intervention group
Group type: EXPERIMENTAL
Intervention: Q‐ter 320 mg + creatine 340 mg
Number of subjects: 67
Study 21462215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 18718555 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment intervention
Number of subjects: 0
Study 18718555 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16931611 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral carnitine supplementation (20 mg/kg/d) at week 1 (n = 6)
Number of subjects: 16
Study 16931611 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral carnitine supplementation (20 mg/kg/d) at week 8 (n = 8)
Number of subjects: 16
Study 16931611 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired analysis of parenteral at week 1 and enteral at week 8 (n = 5)
Number of subjects: 16
Study 15302144 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (compensatory training, emphasizing enhancement of visual and somatosensory function, and balance training) administered three times weekly for 12 weeks.
Number of subjects: 21
Study 15302144 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (language development activities) administered three times weekly for 12 weeks.
Number of subjects: 21
Study 15302144 — intervention group
Group type: EXPERIMENTAL
Intervention: Merged data from both groups after exercise intervention.
Number of subjects: 21
Study 11403983 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/day PO
Number of subjects: 29
Study 11403983 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 10 mg/day PO
Number of subjects: 29
Study 11403983 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 29
Study 9514556 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of pain
Number of subjects: 160
Study 8087820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates (intravenous, oral, or transdermal)
Number of subjects: 80000
Study 8087820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates (combined with lisinopril)
Number of subjects: 80000
Study 8087820 — intervention group
Group type: COMPARATOR
Intervention: Control group (ACE-inhibition strategy)
Number of subjects: 80000
Study 2832598 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous progestin (2.5 mg daily)
Number of subjects: 36
Study 2832598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic progestin (5 mg daily or 5 mg during the last 12 days of a 28-day cycle)
Number of subjects: 36
Study 29890800 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior wall with screw and posterior with plate (SP)
Number of subjects: 16
Study 29890800 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior wall with plate and posterior wall with screw (PS)
Number of subjects: 16
Study 29890800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both wall with plate (PP)
Number of subjects: 16
Study 29890800 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (complete acetabulum)
Number of subjects: 16
Study 27190539 — intervention group
Group type: EXPERIMENTAL
Intervention: BrainPower Advanced (n=47)
Number of subjects: 98
Study 27190539 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=51)
Number of subjects: 98
Study 24398576 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (frequency of 50 Hz, amplitude of 2 mm, four 1-min series with 1-min rest intervals in three body positions)
Number of subjects: 43
Study 24398576 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 43
Study 23740686 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) 500 µg daily for 8 weeks
Number of subjects: 50
Study 23740686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20646353 — intervention group
Group type: EXPERIMENTAL
Intervention: bLf 100 mg/twice/day
Number of subjects: 2
Study 20646353 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate 520 mg/day
Number of subjects: 2
Study 18403387 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal ventricular lead implantation
Number of subjects: 98
Study 18403387 — intervention group
Group type: COMPARATOR
Intervention: Standard apical pacing
Number of subjects: 98
Study 16884565 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐health application with a diabetes management system and a home care link
Number of subjects: 175
Study 16884565 — intervention group
Group type: COMPARATOR
Intervention: Usual care (regular general practitioner visits every three months)
Number of subjects: 175
Study 16884565 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐health application
Number of subjects: 175
Study 12801195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold weather outdoor training (winter)
Number of subjects: 1405
Study 12801195 — intervention group
Group type: COMPARATOR
Intervention: Warm weather outdoor training (summer)
Number of subjects: 1405
Study 10825328 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (PVB)
Number of subjects: 60
Study 10825328 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 60
Study 8837669 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT with standardized Dermatophagoides pteronyssinus extract
Number of subjects: 40
Study 8469455 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted delivery
Number of subjects: 278
Study 8469455 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps-assisted delivery
Number of subjects: 278
Study 8469455 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous vaginal delivery
Number of subjects: 278
Study 8469455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential vacuum and forceps-assisted delivery
Number of subjects: 278
Study 8469455 — intervention group
Group type: COMPARATOR
Intervention: Fetal distress
Number of subjects: 278
Study 8469455 — intervention group
Group type: COMPARATOR
Intervention: Decreased birth weight for gestation
Number of subjects: 278
Study 8469455 — intervention group
Group type: COMPARATOR
Intervention: Umbilical artery pH less than 7.20
Number of subjects: 278
Study 8469455 — intervention group
Group type: COMPARATOR
Intervention: Second stage of labor less than 30 minutes
Number of subjects: 278
Study 8469455 — intervention group
Group type: COMPARATOR
Intervention: Vacuum-assisted delivery among low birth weight infants
Number of subjects: 278
Study 8469455 — intervention group
Group type: COMPARATOR
Intervention: Short second stage of labor
Number of subjects: 278
Study 8469455 — intervention group
Group type: COMPARATOR
Intervention: Fetal acidosis
Number of subjects: 278
Study 8469455 — intervention group
Group type: COMPARATOR
Intervention: Sequential use of vacuum and forceps for assisted delivery
Number of subjects: 278
Study 3780285 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional propranolol ('Inderal')
Number of subjects: 13
Study 3780285 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol ('Inderal' LA)
Number of subjects: 13
Study 3780285 — intervention group
Group type: COMPARATOR
Intervention: Both formulations of propranolol
Number of subjects: 13
Study 28985685 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous stretching of the Achilles tendon and plantar fascia
Number of subjects: 50
Study 28985685 — intervention group
Group type: COMPARATOR
Intervention: Stretching of the Achilles tendon only
Number of subjects: 50
Study 27196818 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-MRI ICD sensing and treatment of ventricular tachyarrhythmias (VT/VF)
Number of subjects: 156
Study 27196818 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection delay due to undersensing pre-MRI
Number of subjects: 156
Study 27196818 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection delay due to undersensing post-MRI
Number of subjects: 156
Study 27196818 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-MRI episodes with detection delay
Number of subjects: 156
Study 27196818 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-MRI episodes with detection delay
Number of subjects: 156
Study 27196818 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum detection delay pre-MRI
Number of subjects: 156
Study 27196818 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum detection delay post-MRI
Number of subjects: 156
Study 27196818 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically significant detection delay
Number of subjects: 156
Study 24762413 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster simulation 7 to 10 months after NRP
Number of subjects: 50
Study 24762413 — intervention group
Group type: COMPARATOR
Intervention: Control group (no booster simulation)
Number of subjects: 50
Study 24762413 — intervention group
Group type: EXPERIMENTAL
Intervention: NICU program
Number of subjects: 50
Study 24762413 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐NICU program
Number of subjects: 50
Study 23438041 — intervention group
Group type: EXPERIMENTAL
Intervention: PMTCT intervention
Number of subjects: 478
Study 23438041 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (health education sessions plus PMTCT)
Number of subjects: 478
Study 18801832 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 microg kg(‐1) min(‐1) remifentanil
Number of subjects: 21
Study 18801832 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 microg kg(‐1) min(‐1) remifentanil
Number of subjects: 21
Study 18801832 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 21
Study 18426146 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sublingual immunotherapy (SLIT) with a 6-grass pollen mixture, once daily for 2 years
Number of subjects: 185
Study 18426146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 16643482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine extended-release (ER) 4 mg once daily
Number of subjects: 163
Study 16643482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 12794521 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 67
Study 10984368 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 microg once daily
Number of subjects: 306
Study 10984368 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 200 microg twice daily
Number of subjects: 306
Study 10984368 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate (MF) 200 microg once daily
Number of subjects: 306
Study 10984368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 8784105 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide 10 micrograms/kg
Number of subjects: 0
Study 8784105 — intervention group
Group type: COMPARATOR
Intervention: Nafarelin 100 micrograms
Number of subjects: 0
Study 1453146 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, 250 mg twice daily
Number of subjects: 453
Study 1453146 — intervention group
Group type: COMPARATOR
Intervention: Penicillin VK, 250 mg three times daily
Number of subjects: 453
Study 6660217 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/kg guava juice (acute i.p. treatment)
Number of subjects: 0
Study 6660217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of guava juice
Number of subjects: 0
Study 6660217 — intervention group
Group type: COMPARATOR
Intervention: Chlorpropamide and metformin (control)
Number of subjects: 0
Study 31536556 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (5-10 ng/mL) with mycophenolic acid (MPA) and basiliximab
Number of subjects: 207
Study 31536556 — intervention group
Group type: COMPARATOR
Intervention: Control group (CNI-based regimen with mycophenolic acid (MPA) and cyclosporine
Number of subjects: 207
Study 29914943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (800 mg q24h) in combination with amphotericin B deoxycholate (1 mg/kg q24h)
Number of subjects: 43
Study 29914943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (1,200 mg q24h)
Number of subjects: 43
Study 29914943 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole monotherapy (from meta-analysis)
Number of subjects: 43
Study 27153252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pork meals (n=19), provided four times/week for 12 weeks
Number of subjects: 48
Study 27153252 — intervention group
Group type: COMPARATOR
Intervention: Chicken meals (n=12), provided four times/week for 12 weeks
Number of subjects: 48
Study 25351016 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral-rich mud compresses
Number of subjects: 44
Study 25351016 — intervention group
Group type: COMPARATOR
Intervention: Mineral-depleted compresses
Number of subjects: 44
Study 22933808 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-band (2-6 Hz) oscillations
Number of subjects: 0
Study 22933808 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-band (8-12 Hz) oscillations
Number of subjects: 0
Study 21109913 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 60
Study 21109913 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 60
Study 18307772 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g FFA PinnoThin
Number of subjects: 42
Study 18307772 — intervention group
Group type: COMPARATOR
Intervention: olive oil control
Number of subjects: 42
Study 15756254 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of outpatient subcutaneous interleukin‐2 (sc‐rIL‐2), subcutaneous interferon‐alpha2a (sc‐rIFN‐alpha2a), and intravenous 5‐fluorouracil (iv‐5‐FU) according to the standard Atzpodien regimen
Number of subjects: 203
Study 15756254 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 203
Study 15756254 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of outpatient sc‐rIL‐2/sc‐rIFN‐alpha2a/iv‐5‐FU-based immunochemotherapy
Number of subjects: 203
Study 12381971 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise program (experimental group)
Number of subjects: 20
Study 12381971 — intervention group
Group type: COMPARATOR
Intervention: Commonly prescribed exercise program (control group)
Number of subjects: 20
Study 10065646 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous placement of titanium implants
Number of subjects: 10
Study 10065646 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed placement of titanium implants
Number of subjects: 10
Study 7772438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudson face mask (oxygen 3 litre min‐1, air 12 litre min‐1)
Number of subjects: 25
Study 7772438 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal prong (oxygen 3 litre min‐1)
Number of subjects: 25
Study 7772438 — intervention group
Group type: EXPERIMENTAL
Intervention: Binasal catheter (oxygen 3 litre min‐1)
Number of subjects: 25
Study 1699272 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/kg/min, intravenously for 6 hours daily for 28 days)
Number of subjects: 109
Study 1699272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical solvent volumes)
Number of subjects: 109
Study 1699272 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 109
Study 1699272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 1090318 — intervention group
Group type: EXPERIMENTAL
Intervention: Two layer technique
Number of subjects: 92
Study 1090318 — intervention group
Group type: COMPARATOR
Intervention: One layer technique
Number of subjects: 92
Study 30674284 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of smartphone and smartband technology with brief counseling on life habits for 3 months
Number of subjects: 160
Study 30674284 — intervention group
Group type: COMPARATOR
Intervention: Counseling only
Number of subjects: 160
Study 28422556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting interrupted by 2 minutes of light-intensity walking every 20 minutes
Number of subjects: 17
Study 28422556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting interrupted by 2 minutes of standing every 20 minutes
Number of subjects: 17
Study 28422556 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting
Number of subjects: 17
Study 26109462 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation (PN) services including education, counseling, and logistical support in their language of choice
Number of subjects: 303
Study 26109462 — intervention group
Group type: COMPARATOR
Intervention: Mailed cancer education materials (control group)
Number of subjects: 303
Study 26109462 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation (PN)
Number of subjects: 303
Study 23788695 — intervention group
Group type: EXPERIMENTAL
Intervention: Consciously resting meditation (CRM)
Number of subjects: 68
Study 23788695 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 68
Study 21774916 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential self-focus
Number of subjects: 0
Study 21774916 — intervention group
Group type: COMPARATOR
Intervention: Analytical self-focus
Number of subjects: 0
Study 19935461 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol Biopsies (PBx)
Number of subjects: 218
Study 19935461 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐II‐converting enzyme inhibitors or angiotensin II receptor blockers
Number of subjects: 218
Study 19935461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PBx)
Number of subjects: 218
Study 17043957 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression anastomosis clip (CAC)
Number of subjects: 40
Study 17043957 — intervention group
Group type: COMPARATOR
Intervention: Stapler
Number of subjects: 40
Study 12742466 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d sirolimus
Number of subjects: 1300
Study 12742466 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/d sirolimus
Number of subjects: 1300
Study 12742466 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus groups
Number of subjects: 1300
Study 12742466 — intervention group
Group type: EXPERIMENTAL
Intervention: Global trial with sirolimus
Number of subjects: 1300
Study 12742466 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus addition to CsA-Pred regimen
Number of subjects: 1300
Study 10868702 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 17
Study 10868702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9113932 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sequential therapy
Number of subjects: 98
Study 8239913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tołpa Torf Preparation (TTP) administered orally, 5 mg daily for three weeks
Number of subjects: 39
Study 8239913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8239913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tołpa Torf Preparation (TTP)
Number of subjects: 39
Study 3104124 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS NTG 40 cm2 (releasing 20 mg of NTG over 24 hours)
Number of subjects: 8
Study 3104124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg SR
Number of subjects: 8
Study 3104124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3104124 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg SR
Number of subjects: 8
Study 3104124 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS NTG and Nifedipine
Number of subjects: 8
Study 3104124 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 8
Study 31479535 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving ≥10% weight loss in the first year after diagnosis
Number of subjects: 867
Study 31479535 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving ≥10% weight loss in the subsequent 1-5 years
Number of subjects: 867
Study 31479535 — intervention group
Group type: COMPARATOR
Intervention: Maintaining the same weight
Number of subjects: 867
Study 30600732 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI‐Z)
Number of subjects: 116
Study 26205903 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids
Number of subjects: 568
Study 26205903 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 568
Study 26205903 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol modifications allowing for inclusion of patients receiving aspirin
Number of subjects: 568
Study 26205903 — intervention group
Group type: COMPARATOR
Intervention: Malaysian participants
Number of subjects: 568
Study 24884942 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-based test for estimation of lung cancer risk
Number of subjects: 0
Study 24884942 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gene-based test)
Number of subjects: 0
Study 20500555 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG) - aerobic and strength exercises without vibration
Number of subjects: 151
Study 20500555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration training group (VTG) - aerobic and strength exercises with vibration
Number of subjects: 151
Study 20500555 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - low-intensity wellness program
Number of subjects: 151
Study 19220383 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomotic-vaginal fistula (AVF)
Number of subjects: 390
Study 19220383 — intervention group
Group type: COMPARATOR
Intervention: Conventional leakage (CL)
Number of subjects: 390